AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the Development of Novel Antibody Therapeutics
Published: May 23, 2012
MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - May 23, 2012) -
MorphoSys AG / AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the Development of Novel Antibody Therapeutics.
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
New Product Category Targets Contract Research Organizations and Pharmaceutical Companies
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its division for research and diagnostic antibodies, AbD Serotec, will launch a series of novel anti-drug antibodies (ADAs) to strengthen its position as a leading provider of diagnostic reagents. Starting with the recent launch of fully human, recombinant antibodies binding Rituximab (Rituxan®) and Trastuzumab (Herceptin®), AbD Serotec plans to expand this product category with antibodies against Alemtuzumab (Campath®), Bevacizumab (Avastin®), Infliximab (Remicade®), Ustekinumab (Stelara®), and Adalimumab (Humira®) in the near future.* Other anti-drug antibodies can be requested as part of the custom antibody service of AbD Serotec.
"Anti-drug antibodies are ideal for preclinical and clinical research to support the development of novel antibody drugs as well as biosimilars," commented Dieter Feger, Head of AbD Serotec. "We see an increasing demand for these tools from clinical research organizations, biopharmaceutical and pharmaceutical companies. Due to the recombinant nature of our HuCAL technology, AbD Serotec is able to deliver an unlimited, secure and batch to batch consistent supply of these assay reagents for extensive clinical studies."
The Human Combinatorial Antibody Library can deliver highly specific, high-affinity monoclonal antibodies against any given antibody drug with unprecedented success rates. The highly specific HuCAL ADAs are developed solely in vitro, pre-adsorbed against any available controls and human serum. An option to screen for inhibiting or neutralizing antibodies is also offered. An unlimited, consistent supply eliminates the need for revalidation of new sources in extensive clinical studies. Other advantages include the possibility to convert selected ADAs into various other human isotypes and Ig subclasses. This provides customers with a single antibody solution for both immune response and pharmacokinetic assays ultimately saving assay development resources.
* Not all anti-drug antibodies might be available in all countries
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company's AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and arYla® are registered trademarks of MorphoSys.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
For more information, please contact:
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332